Acrivon therapeutics reports initial positive clinical data for acr-368 and pipeline program progress today at corporate r&d event

•  initial acr-368 phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 oncosignature-positive and 16 oncosignature-negative) are being presented•  a 50% confirmed overall response rate observed with acr-368 in oncosignature-positive gynecological (ovarian and endometrial) cancers•  initial clinical validation of ap3 patient selection platform, demonstrated ability to prospectively predict acr-368 recist responders (p-value = 0.0038)•  acr-2316, a potential first-in-class dual wee1/pkmyt1 inhibitor, ind timeline accelerated with filing now expected in q3 2024•  acrivon hosts corporate r&d event webcast today at 4:15 pm et
ACRV Ratings Summary
ACRV Quant Ranking